Roughly 20-40% of weight lost on a GLP-1 is lean mass, not fat
In a randomized controlled trial, participants who used semaglutide in conjunction with lifestyle interventions lost nearly 10-15% of their baseline body weight, compared to 2.5-5% in the placebo group
has received research support for the University of Florida as principal investigator from Boehringer Ingelheim, Echosens, Inventiva, LabCorp and Perspectum and has served as a consultant for Aligos Therapeutics, Arrowhead, AstraZeneca, 89bio, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Prosciento, Sagimet Biosciences, Siemens USA and Terns Pharmaceuticals
This is the same as the US version
It increases the risk of: Type 2 diabetes MASLD (metabolic dysfunction-associated steatotic liver disease, formerly called NAFLD) Cardiovascular disease The loss of estrogen also accelerates sarcopenia, the loss of lean muscle mass, which further slows metabolism and reduces energy expenditure
PMID: 1985738